Sun, Apr 20, 2014, 7:37 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

bobbifleiss 7 posts  |  Last Activity: Mar 4, 2014 10:24 AM Member since: Sep 28, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bobbifleiss by bobbifleiss Mar 4, 2014 10:24 AM Flag

    We're getting close to the big data announcement. Just a few short months away, and if positive, NBS could triple. This stock is in no way priced as one with a billion dollar drug in its pipeline.

  • bobbifleiss by bobbifleiss Feb 24, 2014 10:05 AM Flag

    Sugar can be linked to high blood glucose levels, obesity, diabetes, cardiovascular disease, Alzheimer's disease, macular degeneration, tooth decay, and addiction. Hence, sugar is worse or just as bad as tobacco. People who have these facts wouldn't argue against stevia, and combined with stevia's growth rate, it clearly appears that stevia is the future of sweeteners. STVF couldn't be more attractive

    Sentiment: Strong Buy

  • bobbifleiss bobbifleiss Feb 21, 2014 9:55 AM Flag

    You're absolutely right.... If you look at stocks to be included in Russell index funds at any given year followed by their three month stock price, almost all outperform the market. Also, Russell is just one of the funds that may include NBS. There is a long line.

    Sentiment: Strong Buy

  • Reply to

    of 50,000 stevia plants

    by bobbifleiss Feb 19, 2014 10:26 AM
    bobbifleiss bobbifleiss Feb 21, 2014 9:54 AM Flag

    The good thing about STVF is that they are a research company of a commodity that doesn't have widespread use in the soda and food industry. Large beverage companies especially are showing a sense of desperation to cut down on calories,but must not sacrifice any taste. We'll see what happens from here but my initial thoughts are that STVF found something even better than what's currently in the market and in development.

  • Reply to

    Think we will steadily climb to $1

    by bourbon_on_my_cornflakes Feb 18, 2014 1:06 PM
    bobbifleiss bobbifleiss Feb 19, 2014 10:36 AM Flag

    I think ONCS definitely sees $1 in the next year. If you look back at last year it was really 3 months that caused ONCS to double. The rest was flat trading.

  • bobbifleiss by bobbifleiss Feb 19, 2014 10:26 AM Flag

    Stevia First releases a PR on 1 single plant that contained a natural gene mutation in an important region of a known stevia enzyme, thereby producing a very unique flavor profile.

    It seems promising, maybe our discussions of Reb are a bit behind the curve. Maybe STVF is working on something even better

    Sentiment: Strong Buy

  • Merck may have the very best single agent anti-PD1 in development, but as an investor I am really worried at their lack of pipeline development to combine MK-3475 with other inhibitors worries me. Read "Immune Checkpoint Blocker Race Heats Up" from yesterday, it paints a nice picture of the industry but after seeing what other companies have it worries me about Merck.

    Merck will be late to the game behind BMY, and by the time it gets on the market, BMY will have Yervoy combined with Nivolumab. Then, there are smaller companies like Lion that have great technology to be combined. Any thoughts?

    Sentiment: Hold

GHDX
26.81-0.02(-0.07%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.